Pfizer (PFE) Insider Shantanu Narayen Buys $50K of Stock

Shantanu Narayen, a notable insider, purchased 2,059 shares of Pfizer Inc. (NYSE: PFE) on June 26, 2026. The shares were bought at an average price of $24.29, totaling about $50,013. This move highlights insider interest in the company.

What Changed in Shantanu Narayen's Pfizer Position

Shantanu Narayen's recent acquisition of 2,059 shares in Pfizer Inc. adds to his holdings in the company. The transaction was not part of a pre-scheduled trading plan, indicating a direct decision to increase his stake.

Other Institutional Activity in Pfizer

Several large funds have also been active in Pfizer Inc. BlackRock, Inc. added 5,195,022 shares, bringing its total to 498,257,550 shares worth approximately $13.99 billion, a 1.1% increase. Vanguard Capital Management LLC opened a new position with 369,430,012 shares valued at about $10.37 billion. State Street Corp increased its holdings by 1,144,701 shares, now holding 301,589,865 shares valued at $8.47 billion, marking a 0.4% increase. Geode Capital Management, LLC grew its position by 3,369,661 shares, ending with 133,561,742 shares worth $3.74 billion, a 2.6% increase. Fisher Asset Management, LLC significantly boosted its stake by 53,012,321 shares, now holding 104,964,427 shares valued at $2.95 billion, a 102% increase.

Pfizer Inc. Stock Down 11.9%

Shares of Pfizer Inc. (NYSE: PFE) traded near $24.37 on Wednesday. The company boasts a market capitalization of approximately $138.4 billion. Pfizer's stock has a P/E ratio of 18.54 and a forward P/E of 8.59, with a beta of 0.295, indicating lower volatility compared to the market. The stock's 52-week range is between $23.11 and $28.75, with a 50-day moving average of $25.97 and a 200-day moving average of $25.87. Pfizer maintains a current ratio of 1.25 and a quick ratio of 0.85, with a debt-to-equity ratio of 71.60.

Recent Earnings

For its most recent quarter, Pfizer reported revenue of $63.32 billion, reflecting a growth rate of 5.4%. The company achieved an earnings per share (EPS) of $1.31. Its net margin stood at 11.83%, and return on equity (ROE) was 8.31%. Pfizer is set to release its next earnings report on August 4, 2026.

Dividend

Pfizer offers a solid dividend with an annual rate of $1.72, yielding 7.08%. The company's dividend payout ratio is 131.3%, reflecting its commitment to returning value to shareholders.

Insider Buying and Selling at Pfizer Inc.

On June 26, 2026, several insiders, including Shantanu Narayen, were active in buying Pfizer shares. James Quincey purchased 1,595 shares, Joseph Echevarria acquired 1,904 shares, and Cyrus Taraporevala bought 1,544 shares. Mortimer Buckley and James Smith also added 1,544 and 1,853 shares, respectively, all at the same price of $24.29 per share.

Analysts Set New Price Targets

On April 29, 2026, Citigroup maintained its hold rating on Pfizer with a price target of $27. CICC initiated coverage with a buy rating and a $33 target on April 16, 2026. UBS and Morgan Stanley both maintained hold ratings with targets of $27 and $28, respectively, in April 2026. The consensus among analysts is a buy recommendation, with an average price target of $29.15 based on 27 opinions.

About Pfizer Inc.

Pfizer Inc., headquartered in New York, NY, is a leading healthcare company engaged in the discovery, development, and marketing of biopharmaceutical products. It operates through segments like Biopharma and Pfizer Ignite, offering a range of products such as vaccines, oncology therapies, and inflammation treatments. The company collaborates with notable partners like BioNTech SE and Bristol-Myers Squibb. Founded in 1849, Pfizer has a global workforce of 75,000, led by CEO Dr. Albert Bourla.

Bottom Line

Shantanu Narayen's recent purchase of Pfizer shares is a notable insider transaction, reflecting potential confidence in the company's future. Investors often watch such insider activities for insights into the company's prospects. It's important to remember that these transactions are backward-looking and might not represent the current position.